Gilead Sciences (GILD) Quarterly Report Leads to Morgan Stanley Reassessment
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowMorgan Stanley has reassessed its outlook for Gilead Sciences (GILD) following the company's recent quarterly report. GILD reported revenue of $6.36 billion for the last quarter, reflecting a year-over-year decrease of 4%. The company's earnings per share (EPS) were reported at $1.58, slightly below analysts' expectations of $1.60. This reassessment by Morgan Stanley could influence investor sentiment and GILD's stock performance in the near term.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Gilead Sciences Inc. (GILD)
Gilead Sciences is a biopharmaceutical company known for its HIV and antiviral therapies.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier GILD news
- Gilead Sciences (GILD) DEF 14A Filing Details for April 21
- Gilead (GILD) acquires Tubulis for $5 billion investment
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
